Pressmeddelande

BioStock: Biosergen advances BSG005 antifungal drug candidate trial

Cision Publicerad: 18 Oct 08:20

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen’s CEO, Tine Olesen, came to BioStock's studio to discuss this milestone, the company’s financing and the next steps ahead.

See the interview with CEO Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/10/biosergen-advances-bsg005-antifungal-drug-candidate-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Biosergen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!